Related references
Note: Only part of the references are listed.The association between risk of limb fracture and type 2 diabetes mellitus
Jie Liu et al.
Oncotarget (2018)
Body weight homeostat that regulates fat mass independently of leptin in rats and mice
John-Olov Jansson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review
Karin Radholm et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Relationship between adiponectin and leptin on osteocalcin in obese adolescents during weight loss therapy
Raquel Munhoz da Silveira Campos et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study
Jenny E. Blau et al.
JCI INSIGHT (2018)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Julio Rosenstock et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
Eirik Softeland et al.
DIABETES CARE (2017)
Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis
Katrine Hygum et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Type 2 Diabetes Mellitus Is Associated With Better Bone Microarchitecture But Lower Bone Material Strength and Poorer Physical Function in Elderly Women: A Population-Based Study
Anna G. Nilsson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
A Mendelian Randomization Study of the Effect of Type-2 Diabetes and Glycemic Traits on Bone Mineral Density
Omar S. Ahmad et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Satish K. Garg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus
Jean-Francois Yale et al.
CLINICAL THERAPEUTICS (2017)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
Darin Ruanpeng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Fracture risk associated with common medications used in treating type 2 diabetes mellitus
Daniel Wolverton et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
Sven Kohler et al.
ADVANCES IN THERAPY (2017)
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
Takashi Kadowaki et al.
DIABETES OBESITY & METABOLISM (2017)
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Gian Paolo Fadini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
Michael Pfeifer et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
Kathryn M. Thrailkill et al.
BONE (2017)
SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice
Kathryn M. Thrailkill et al.
BONE (2016)
Effects of diabetes drugs on the skeleton
Christian Meier et al.
BONE (2016)
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals
Yuji Ishibashi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
H. L. Tang et al.
DIABETES OBESITY & METABOLISM (2016)
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study
M. R. Laurent et al.
OSTEOPOROSIS INTERNATIONAL (2016)
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Deepson S Shyangdan et al.
BMJ Open (2016)
Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
Markus F. Scheerer et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
Christopher S. Kovacs et al.
CLINICAL THERAPEUTICS (2015)
Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials
Jessica Zibellini et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
Ann V. Schwartz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Possible adverse effects of SGLT2 inhibitors on bone
Simeon I. Taylor et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Bruce Neal et al.
DIABETES CARE (2015)
Defects in cortical microarchitecture among African-American women with type 2 diabetes
E. W. Yu et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhong-Ning Zhu et al.
BONE (2014)
Proximal Tubule Function and Response to Acidosis
Norman P. Curthoys et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Role of local vitamin D signaling and cellular calcium transport system in bone homeostasis
Ritsuko Masuyama
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
In Vivo Assessment of Bone Quality in Postmenopausal Women With Type 2 Diabetes
Joshua N. Farr et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Matthew R. Weir et al.
JOURNAL OF CLINICAL HYPERTENSION (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
M. Suzuki et al.
NUTRITION & DIABETES (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
Antonella Napolitano et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY (2014)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
O. Ljunggren et al.
DIABETES OBESITY & METABOLISM (2012)
Type 2 Diabetes and Bone
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Circulating Osteogenic Precursor Cells in Type 2 Diabetes Mellitus
J. S. Manavalan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism
L. Darryl Quarles
NATURE REVIEWS ENDOCRINOLOGY (2012)
Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes
Yijun Zhou et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis
Stavros C. Manolagas
ENDOCRINE REVIEWS (2010)
Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells
Masaaki Inaba et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Bone Mass and Strength in Older Men With Type 2 Diabetes: The Osteoporotic Fractures in Men Study
Moira A. Petit et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
High-Resolution Peripheral Quantitative Computed Tomographic Imaging of Cortical and Trabecular Bone Microarchitecture in Patients with Type 2 Diabetes Mellitus
Andrew J. Burghardt et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus
M. Saito et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
In Vitro and in Vivo Effects of Adiponectin on Bone
Garry A. Williams et al.
ENDOCRINOLOGY (2009)
Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus
Tomoko Tamura et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis
P. Vestergaard
OSTEOPOROSIS INTERNATIONAL (2007)
Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats
M. Saito et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women
Sherri-Ann M. Burnett et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Glycation endproducts in osteoporosis - Is there a pathophysiologic importance?
Gert E. Hein
CLINICA CHIMICA ACTA (2006)
Diabetes and bone loss at the hip in older black and white adults
AV Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Share Paper
